Market Cap : 218.58 B | Enterprise Value : 237.69 B | PE Ratio : 35.38 | PB Ratio : 4.87 |
---|
NYSE:DHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:DHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Danaher has the Profitability Rank of 8. It has a higher profitability and may stay that way.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Danaher's Operating Margin % for the quarter that ended in Jun. 2022 was 28.45%. As of today, Danaher's Piotroski F-Score is 8.
For the Diagnostics & Research subindustry, Danaher's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Danaher's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Danaher has the Profitability Rank of 8. It has a higher profitability and may stay that way.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Danaher's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | 2205 | / | 7751 | |
= | 28.45 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Danaher has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Danaher Corp operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Danaher's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Couchara Georgeann | officer: SVP, Human Resources | 2200 PENNSYLVANIA AVENUE, NW SUITE 800W WASHINGTON DC 20037 |
Bouda Christopher | officer: VP, Chief Accounting Officer | 2200 PENNSYLVANIA AVENUE, NW SUITE 800W WASHINGTON DC 20037 |
Sanders A Shane | director | 2200 PENNSYLVANIA AVENUE, NW SUITE 800W WASHINGTON DC 20037 |
Honeycutt Jennifer | officer: Executive Vice President | 2200 PENNSYLVANIA AVENUE SUITE 800W WASHINGTON DC 20037 |
Gutierrez-ramos Jose-carlos | officer: SVP, Chief Scientific Officer | C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142 |
Mega Jessica L | director | 2200 PENNSYLVANIA AVENUE SUITE 800W WASHINGTON DC 20037 |
Sabeti Pardis C | director | 2200 PENNSYLVANIA AVENUE SUITE 800W WASHINGTON DC 20037 |
Mcgrew Matthew | officer: EVP & Chief Financial Officer | 2200 PENNSYLVANIA AVENUE, NW SUITE 800 W WASHINGTON DC 20010 |
Weidemanis Joakim | officer: Executive Vice President | 2200 PENNSYLVANIA AVENUE SUITE 800W WASHINGTON DC 20037 |
Rales Steven M | director, officer: Chairman | 2200 PENNSYLVANIA AVENUE, NW SUITE 800W WASHINGTON DC 20037 |
Stevens Raymond C | director | 2200 PENNSYLVANIA AVENUE SUITE 800W WASHINGTON DC 20037 |
Blair Rainer | officer: Executive Vice President | 2200 PENNSYLVANIA AVENUE, NW SUITE 800W WASHINGTON DC 20037 |
Hugin Robert J | director | C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054 |
Ellis Brian W | officer: Senior Vice President - GC | 2200 PENNSYLVANIA AVENUE, NW WASHINGTON DC 20037 |
Rales Mitchell P | director, officer: Chairman of Exec. Committee | 11790 GLEN ROAD POTOMAC MD 20854 |
From GuruFocus
By PRNewswire 12-07-2021
By PRNewswire 02-23-2022
By PRNewswire 03-01-2022
Other Sources
By Seekingalpha 2022-03-07
By Zacks 2022-03-04
By Zacks 2022-03-31
By Zacks 2022-03-09
By Zacks 2022-01-27
By Zacks 2022-01-26
By Zacks 2022-01-25
By Zacks 2022-02-15
By Zacks 2022-01-25
By Zacks 2022-04-04
By Zacks 2022-03-17
By Seekingalpha 2022-03-08
By Zacks 2022-02-14
By Zacks 2022-03-11